A statin cut heart attacks in healthy people over 70 but did not help them live longer without disability
Table of Contents
1.0 Summary
STAREE, a placebo-controlled trial run through general practices in Australia, gave atorvastatin 40 mg a day or a placebo to 9,971 independently living adults aged 70 or older who had no heart disease, diabetes or dementia. Over a median of 5.9 years, atorvastatin lowered the rate of major cardiovascular events (death from heart disease, heart attack, stroke, or a procedure to reopen a coronary artery) by 30%, with 297 events against 412. Most of that benefit came from fewer nonfatal heart attacks and fewer artery-opening procedures. The trial’s other primary measure, survival without dementia or lasting physical disability, did not improve, and cardiovascular deaths and dementia did not differ between the groups. The participants were healthier than many older patients and mostly White, and only 55.6% of those assigned atorvastatin were still taking it at five years. This summary draws on news coverage of the congress presentation, not the journal article itself.
2.0 Key Points
- In 9,971 adults aged 70 or older without heart disease, diabetes or dementia, atorvastatin 40 mg daily reduced major cardiovascular events by 30% compared with placebo over a median 5.9 years (297 vs 412 events; hazard ratio 0.70, 95% CI 0.61 to 0.82).
- The reduction came mainly from nonfatal heart attacks (HR 0.57) and coronary revascularization (HR 0.57); stroke (HR 0.87, 95% CI 0.68 to 1.11) and cardiovascular death (HR 1.00, 95% CI 0.72 to 1.37) did not differ significantly.
- Disability-free survival, the co-primary endpoint, did not improve (637 vs 676 events; HR 0.94, 95% CI 0.84 to 1.05), and 80% of deaths in the trial were from causes other than cardiovascular disease.
- Dementia rates were similar in the two groups, and serious adverse events occurred in 2.7% of each, though musculoskeletal, liver-related and diabetes-related adverse events were more common with atorvastatin.
- Participants were relatively healthy, independently living and predominantly White, and adherence to atorvastatin fell to 55.6% by five years.
3.0 Evidence base
Statins are well established for people who already have cardiovascular disease or who are at high risk, such as those with diabetes [1]. Whether to start one in a healthy older adult has been less clear. Fewer than a quarter of the participants in the trials behind earlier pooled analyses were older than 70, and the investigators said guidelines had not been able to make strong recommendations for this age group [1].
STAREE was built to answer that. It was an investigator-initiated, double-blind trial run through general practices across Australia, and it randomly assigned 9,971 independently living adults aged 70 or older, with no cardiovascular disease, diabetes or dementia, to atorvastatin or placebo [1]. Their mean age was 74.7 years, 51.9% were women and 40% were 75 or older. Atorvastatin started at 20 mg a day and rose to 40 mg after four weeks if tolerated [1]. Average LDL cholesterol at the start was about 127 mg/dL. By the end of follow-up it had fallen by a mean of 48 mg/dL with atorvastatin and 16 mg/dL with placebo [1].
The trial had two primary endpoints. The first was major cardiovascular events: death from cardiovascular causes, nonfatal heart attack, stroke, or coronary revascularization, meaning a stent or bypass surgery [2]. After a median 5.9 years, 297 people on atorvastatin and 412 on placebo had such an event, a 30% relative reduction (hazard ratio 0.70, 95% CI 0.61 to 0.82, P < .001) [1]. The effect looked similar in people aged 70 to 74 and in those 75 and older, and it was consistent across subgroups defined by LDL cholesterol, blood pressure, body mass index and kidney function [1].
Most of the benefit came from events people survive. Heart attacks were less common with atorvastatin (HR 0.57, 95% CI 0.43 to 0.75), and so were revascularization procedures (HR 0.57, 95% CI 0.45 to 0.72). Stroke was numerically less frequent, but the confidence interval crossed 1 (HR 0.87, 95% CI 0.68 to 1.11). Cardiovascular deaths did not differ (HR 1.00, 95% CI 0.72 to 1.37) [1].
The second primary endpoint was disability-free survival, which counts death, dementia, or persistent physical disability. It occurred in 637 people on atorvastatin and 676 on placebo, a difference that was not statistically significant (HR 0.94, 95% CI 0.84 to 1.05, P = .25) [1]. The investigators offered one likely explanation: 80% of the deaths in the trial were from causes other than cardiovascular disease, which limits how far preventing heart attacks could move this measure [1, 2]. Dementia occurred at 10.6 per 1,000 person-years with atorvastatin and 10.3 with placebo (HR 1.03, 95% CI 0.87 to 1.21), showing neither harm nor benefit [1].
Serious adverse events occurred in 2.7% of participants in both groups. Musculoskeletal, liver-related and diabetes-related adverse events were more common with atorvastatin [1, 2]. About half of the participants already reported a muscle or joint problem when they enrolled [1].
4.0 Where it fits in practice
The discussant at the congress, Francois Mach of Geneva University Hospital, drew two conclusions. Age alone should no longer be a reason to withhold a statin for primary prevention, and STAREE does not mean that every person 70 or older should automatically take one [1]. He said the decision should account for life expectancy, competing risks, the burden of treatment and the patient’s own priorities [1]. The lead investigator said she hopes to see guidelines updated to reflect the findings [2].
For a healthy older adult, the trade this trial describes is fewer nonfatal heart attacks and fewer stents on one side, and a daily pill with more muscle and other side effects on the other, without evidence of a longer life or a longer period of independence. That is a decision to talk through with the patient rather than a default in either direction.
How this site estimates risk before a statin decision is set out in /clinical/04-risk-stratification.html, and statin choice and dosing are in /clinical/05-treatment-pathways.html. For patients who have had trouble tolerating a statin, see /clinical/08-statin-intolerance.html.
5.0 Open questions
The people in STAREE were relatively healthy, lived independently and were mostly White and English-speaking. Frail older adults, those with several chronic conditions, and the very old were underrepresented, so the results may not apply to them [1].
Adherence fell steadily. Of those assigned atorvastatin, 80.2% were still taking it at one year, 66.1% at three years and 55.6% at five. Open-label statin use was also more common in the placebo group. Both push the measured difference toward zero, so the investigators consider the treatment effect a conservative estimate [1].
The discussant named the questions the trial leaves open: which older adults should be treated, and for how long, and whether preventing an event gives them a more meaningful life [1]. Disability-free survival was meant to capture that last point, and on that measure the trial found no difference.
This summary is based on news coverage of the ESC Congress 2026 presentation, not the full journal article [1, 2].
This summary is provided for clinical decision support only and does not replace individualized clinical judgment. Findings are summarized from the cited primary sources; consult those sources before changing practice.
Version History
| Version | Date | Description |
|---|---|---|
| 1.0.0 | 2026-09-14 | Initial release |
References
- Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE. 2026-08-29. https://www.medscape.com/viewarticle/staree-trial-atorvastatin-cuts-major-cv-events-30-older-2026a1000ukk?src=rss.
- STAREE: Can Statin Therapy Help Prevent CV Events in Healthy, Community-Dwelling, Older Adults?. https://www.acc.org/Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-215am-staree-esc-2026.